Encellin, a San Francisco, CA-based biotechnology company developing a cell encapsulation platform with an initial focus on Type 1 Diabetes (T1D), closed a $9.9M financing round.
The round was led by Khosla Ventures, with participation from Y Combinator.
Led by Crystal Nyitray, Ph.D., CEO & Co-Founder, Encellin has developed an Encapsulated Cell Replacement Therapy (EnCRT) to isolate therapeutic cells from the body’s immune system, to help therapeutic cells survive in the body. Once implanted, cells within the porous EnCRT are able to exchange the biomolecules with the body, which Encellin seeks to demonstrate will provide a therapeutic benefit and function as a living medicine.
Preclinical data with its first candidate, using ENC-201 in T1D, reported no fibrosis, or immune response, while maintaining cell viability and function. Preclinical data also demonstrated that primary islets encapsulated with Encellin’s EnCRT may be able to reverse T1D.
The new funding will advance a Phase 1 clinical trial evaluating subcutaneous transplantation of primary islets within Encellin’s EnCRT in T1D. First-in-human data from the Phase 1 study is expected next year. The financing will also be used for team expansion and further development of the technology platform.
Encellin, a San Francisco, CA-based biotechnology company developing a cell encapsulation platform with an initial focus on Type 1 Diabetes (T1D), closed a $9.9M financing round. Best wishes to everyone in the group. This will be a huge accomplishment for them in the future.
Shishir Gupta, The Founder & CEO of StartupLanes
About us: StartupLanes is an ecosystem for Startups and Investors. Collaborate or find a co-founder, it’s a platform for Entrepreneurs. We love startups! A place for Angel Investors and Venture Capitalists to find investing opportunities in startups. Validate your idea, Learn & Execute.
Startups looking for funding may apply through StartupLanes Funding Application.
Angel Investors Register Free to explore exciting startup investment opportunities.